Compensatory mechanisms in experimental and human parkinsonism: Towards a dynamic approach

Progress in Neurobiology

Volumn 55, Issue 2, 1998, Pages 93-116

  Bezard, Erwan ^a   Gross, Christian E ^a  

^a Basal Gang   (France)

Author keywords

[No Author keywords available]

Indexed keywords

ADAPTATION; CORPUS STRIATUM; DOPAMINERGIC NERVE CELL; HUMAN; NERVE CELL PLASTICITY; NIGRONEOSTRIATAL SYSTEM; NONHUMAN; PARKINSON DISEASE; PARKINSONISM; PATHOPHYSIOLOGY; PRIORITY JOURNAL; REVIEW; SUBSTANTIA NIGRA;

EID: 0031960890     PISSN: 03010082     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0301-0082(98)00006-9     Document Type: Article

References (373)

1. Abercrombie E. D., Bonatz A. E., Zigmond M. J. Effects of L-DOPA on extracellular dopamine in striatum of normal and 6-hydroxydopamine-treated rats. Brain Res. 525:1990;36-44.
2. Aghajanian, G. K. and Bunney, B. S. (1973). Central dopaminergic neurons: neurophysiological identification and responses to drugs. In Frontiers in catecholamine research, (Eds S. H. Snyder, and E. Usdin), pp. 331-338. Pergamon Press, New York.
3. Agid Y. Parkinson's disease: pathophysiology. Lancet. 337:1991;1321-1323.
4. Agid Y., Javoy F., Glowinski J. Hyperactivity of remaining dopaminergic neurones after partial destruction of the nigro-striatal dopaminergic system in the rat. Nature. 245:1973;150-151.
5. Agid, Y., Javoy-Agid, F. and Ruberg, M. (1987). Biochemistry of neurotransmitters in Parkinson's disease. In Movement disorders II (Eds C. D. Marsden, and S. Fahn), pp. 166-200. Butterworths, London.
6. Agnati L. F., Zolli M., Strömberg I., Fuxe K. Intercellular communication in the brain: wiring versus volume transmission. Neuroscience. 69:1995;711-726.
7. Albanese A., Granata R., Gregori B., Piccardi M. P., Colosimo C., Tonali P. Chronic administration of MPTP to monkeys: behavioural, morphological and biochemical correlates. Neuroscience. 55:1993;823-832.
8. Albin R. L., Young A. B., Penney J. B. The functional anatomy of basal ganglia disorders. Trends Neurosci. 12:1989;366-375.
9. 2 receptor on cholinergic interneurons of the rat neostriatum: an electron microscopic immunocytochemical double labeling study. Paper presented at the Soc. Neurosci. Abstr., New Orleans.
10. Alexander G. E., Crutcher M. D. Functional architecture of basal ganglia circuits: neural substrates of parallel processing. Trends Neurosci. 13:1990;266-271.
11. Altar C. A., Marien M. R., Marshall J. F. Time course of adaptations in dopamine biosynthesis, metabolism, and release following nigrostriatal lesions: implications for behavioral recovery from brain injury. J. Neurochem. 48:1987;390-399.
12. Altman J. Are neurons formed in the brains of adult mammals? Science. 135:1962;1127-1128.
13. Anglade, P., Blanchard, V., Raisman-Vozari, R., Faucheux, B. A., Herrero, M. T., Obeso, J. A., Mouatt-Prigent, A., Kastner, A., Strada, O., Javoy-Agid, F., Agid, Y. and Hirsch, E. C. (1996). Is dopaminergic cell death accompanied by concomitant nerve plasticity? In Advances in neurology (Eds L. Battistin, G. Scarlato, T. Caraceni, and S. Ruggieri), Vol. 69, pp. 195-208. Lippincott-Raven Publishers, Philadelphia.
14. Anglade P., Tsuji S., Javoy-Agid F., Agid Y., Hirsch E. C. Plasticity of nerve afferents to nigrostriatal neurons in Parkinson's disease. Ann. Neurol. 37:1995;265-272.
15. Ariano M. A. Striatal dopamine receptor distribution following chemical lesion of the nigrostriatal pathway. Brain Res. 443:1988;204-214.
16. Aziz T. Z., Peggs D., Sambrook M. A., Crossman A. R. Lesion of the subthalamic nucleus for the alleviation of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)-induced parkinsonism in the primate. Mov. Disord. 6:1991;288-292.
17. Bankiewicz K. S., Oldfield E. H., Chiueh C. C., Doppamn J. L., Jacobowitz D. M., Kopin I. J. Hemiparkinsonism in monkeys after unilateral internal carotid artery infusion of MPTP. Life Sci. 39:1986;7-16.
18. Bankiewicz K. S., Plunkett R. J., Jacobowitz D. M., Porrino L., DiPorzio U., London W. T., Kopin I. J., Oldfield E. H. The effect of fetal mesencephalon implants on primate MPTP-induced parkinsonism. J. Neurosurg. 72:1990;231-244.
19. Bankiewicz K. S., Plunkett R. J., Kopin I. J., Jacobowitz D. M., London W. T., Oldfield E. H. Transient behavioral recovery in hemiparkinsonian primates after adrenal medullary allografts. Prog. Brain Res. 78:1988;543-549.
20. Benazzouz A., Boraud T., Féger J., Burbaud P., Bioulac B., Gross C. Alleviation of experimental hemiparkinsonism by high frequency stimulation of the subthalamic nucleus in primates: a comparison with L-Dopa treatment. Mov. Disord. 11:1996;627-632.
21. Benazzouz A., Gross C., Bioulac B. MPTP-induced hemiparkinsonism in monkeys: behavioral, mechanographic, electromyographic and immunohistochemical studies. Exp. Brain Res. 90:1992;116-120.
22. Benazzouz A., Gross C., Feger J., Boraud T., Bioulac B. Reversal of rigidity and improvement in motor performance by subthalamic high frequency stimulation in MPTP-treated monkeys. Eur. J. Neurosci. 5:1993;382-389.
23. Beninato M., Spencer R. F. A cholinergic projection to the rat substantia nigra from the pedunculopontine tegmental nucleus. Brain Res. 412:1987;169-174.
24. Beninato M., Spencer R. F. The cholinergic innervation of the rat substantia nigra: a light and electron microscopic immunohistochemical study. Exp. Brain Res. 72:1988;178-184.
25. Bergman H., Wichmann T., Delong M. R. Reversal of experimental parkinsonism by lesion of the subthalamic nucleus. Science. 249:1990;1436-1438.
26. Bergman H., Wichmann T., Karmon B., Delong M. R. The primate subthalamic nucleus. II. Neuronal activity in the MPTP model of parkinsonism. J. Neurophysiol. 72:1994;507-520.
27. Bernheimer H., Birkmayer W., Hornykiewicz O., Jellinger K., Seitelberger F. Brain dopamine and the syndromes of Parkinson and Huntington. Clinical, morphological and neurochemical correlations. J. Neurol. Sci. 20:1973;415-455.
28. Besson M., Cheramy A., Feltz P., Glowinski J. Release of newly synthesized dopamine from dopamine-containing terminals in the striatum of the rat. P. Natl. Acad. Sci. USA. 62:1969;741-748.
29. Betarbet, R., Levey, A. I. and Greenamyre, J. T. (1997a). Dopaminergic neurons of the primate striatum. Paper presented at the Soc. Neurosci. Abstr., New Orleans.
30. Betarbet R., Turner R., Chocklan V., DeLong M. R., Allers K. A., Walters J., Levey A. I., Greenamyre J. T. Dopaminergic neurons intrinsic to the primate striatum. J. Neurosci. 17:1997;6761-6788.
31. Bezard, E., Bioulac, B. and Gross, C. (1998). Glutamatergic compensatory mechanisms in experimental parkinsonism. Prog. Neuro-Psychopharmacol. 22, (in press).
32. Bezard, E., Boraud, T., Bioulac, B., Dufy, B. and Gross, C. E. (1996). Blockage of SNc glutamatergic inputs, a new base for presymtomatic diagnosis in Parkinson's disease? Paper presented at the Soc. Neurosci. Abstr., Washington.
33. Bezard, E., Boraud, T., Bioulac, B. and Gross, C. (1997a) Compensatory effects of glutamatergic inputs to the substantia nigra pars compacta in experimental parkinsonism. Neuroscience 81, 399-404.
34. Bezard, E., Boraud, T., Bioulac, B. and Gross, C. E. (1997b) Presymptomatic revelation of experimental parkinsonism. Neuroreport, 8, 435-438.
35. Bezard, E., Deloire, X., Boraud, T., Bioulac, B. and Gross, C. (1997c). Electrophysiological study of SNc dopaminergic neurones in the normal monkey. Paper presented at the Soc. Neurosci. Abstr., New Orleans.
36. Bezard, E., Dovero, S., Bioulac, B. and Gross, C. (1997d) Kinetics of nigral degeneration in a chronic model of MPTP-treated mice. Neurosci. Lett. 234, 43-46.
37. Bezard, E., Imbert, C., Deloire, X., Bioulac, B. and Gross, C. (1977e) A chronic MPTP model reproducing the slow evolution of Parkinson's disease: evolution of motor symptoms in the monkey. Brain Res. 766, 107-112.
38. Birkmayer, W., Danielczyk, W., Neumayer, E. and Riederer, P. (1975). Dopaminergic supersensitivity in parkinsonism. In Advances in neurology (Eds D. B. Calne, T. N. Chase, and A. Barbeau), Vol. 9, pp. 121-129. Raven Press, New York.
39. Birkmayer W., Hornykiewicz O. Der L-Dopa Effekt bei der Parkinson-Akinese. Wien. klin. Wschr. 73:1961;787.
40. Birkmayer W., Hornykiewicz O. Der L-Dopa Effekt beim Parkinson-Syndrom des Menschen. Zur Pathogenese und Behandlung der Parkinson-Akinese. Arch. Psychiat. Nervenkr. 203:1962;560-574.
41. Bjelke B., Strömberg I., O'Connor W. T., Andbjer B., Agnati L. F., Fuxe K. Evidence for volume transmission in the dopamine denervated neostriatum of the rat after a unilateral nigral 6-OHDA microinjection. Studies with systemic D-amphetamine treatment. Brain Res. 662:1994;11-24.
42. Björklund A., Stenevi U. Regeneration of monoaminergic and cholinergic neurons in the mammalian central nervous system. Physiol. Rev. 59:1979;62-100.
43. Blanchard V., Anglade P., Dziewczapolski G., Savasta M., Agid Y., Raisman-Vozari R. Dopaminergic sprouting in the rat striatum after partial lesion of the SN. Brain Res. 709:1996;319-325.
44. Blanchard V., Christin M., Vyas S., Savasta M., Javoy-Agid F., Feuerstein C., Agid Y., Raisman-Vozari R. Long-term induction of tyrosine hydroxylase: compensatory response to partial degeneration of the dopaminergic nigrostriatal system in the rat brain. J. Neurochem. 64:1995;1669-1679.
45. Blanchard V., Raisman-Vozari R., Vyas S., Michel P. P., Javoy-Agid F., Uhl G., Agid Y. Differential expression of tyrosine hydroxylase and membrane dopamine transporter genes in subpopulations of dopaminergic neurones of the rat mesencephalon. Mol. Brain Res. 22:1994;29-40.
46. Blandini F., Porter R. H. P., Greenamyre J. T. Glutamate and Parkinson's disease. Mol. Neurobiol. 12:1996;73-94.
47. Bloom F. E., Algeria S., Gropetti A., Revuelta A., Costa E. Lesions of central norepinephrine terminals with 6-hydroxydopamine: biochemistry and fine structure. Science. 166:1969;1284-1286.
48. Bohn M. C., Cupit L., Marciano F., Gash D. M. Adrenal medulla grafts enhance recovery of striatal dopaminergic fibers. Science. 237:1987;913-916.
49. 3H-spiperone binding, dopamine and HVA concentrations in Parkinson's disease and supranuclear palsy. Eur. J. Pharmacol. 99:1984;167-175.
50. Bolam J. P., Smith Y. The GABA and substance P input to dopaminergic neurons of the substantia nigra of the rat. Brain Res. 529:1990;57-78.
51. Boraud T., Bezard E., Bioulac B., Gross C. High frequency stimulation of the internal globus pallidus reduces the higher firing frequency of its neurons in the MPTP-treated monkey model of Parkinson's disease. Neurosci. Lett. 215:1996;17-20.
52. Braak H., Braak E., Yilmazer D., Vos R. A. I. D., Jansen E. N. H., Bohl J. Pattern of brain destruction in Parkinson's and Alzheimer's diseases. J. Neural Transm. 103:1996;455-490.
53. 2 dopamine agonists into nucleus accumbens and striatum without changing dopamine antagonist binding. J. Pharmacol. Exp. Ther. 240:1987;167-176.
54. Breese G. R., Smith R. D., Cooper B. R., Grant L. D. Alterations in the consumatory behavior of rats following intracisternal injection of 6-hydroxydopamine. Pharmacol. Biochem. Behav. 1:1973;319-328.
55. Bunney B. S., Walters J. R., Roth R. H., Aghajanian G. K. Dopaminergic neurons: effect of antipsychotic drugs and amphetamine on single cell activity. J. Pharmacol. Exp. Ther. 185:1973;560-571.
56. 1 receptor supersensitivity in the rat striatum after unilateral 6-hydroxydopamine lesions. Eur. J. Pharmacol. 126:1986;347-348.
57. Burns R. S., Chiueh C. C., Markey S. P., Ebert M. H., Jacobowitz D. J., Kopin I. J. A primate model of parkinsonism: selective destruction of dopaminergic neurons in the pars compacta of the substantia nigra by N-methyl-4-phenyl-1,2,3,6-tetrahydropyridine P. Natl. Acad. Sci. USA. 80:1983;4546-4550.
58. 1 dopamine receptor immunoreactivity in rat striatonigral neurons and its relation with dopaminergic innervation. Brain Res. 730:1996;17-31.
59. Calabresi P., Mercuri N. B., Sancessario G., Bernardi G. Electrophysiology of dopamine-denervated striatal neurons. Implications for Parkinson's disease. Brain. 116:1993;433-452.
60. Calabresi P., Pisani A., Centonze D., Bernardi G. Synaptic plasticity and physiological interactions between dopamine and glutamate in the striatum. Neurosci. Biobehav. Rev. 21:1997;519-523.
61. Carter C. J. Glutamatergic pathways from the medial prefrontal cortex to the anterior striatum, nucleus accumbens, and substantia nigra. Br. J. Pharmacol. 70:1980;50P.
62. Carvey P. M., Ptak L. R., Kao L., Cleanse H. L. Striatal homogenates from animals chronically treated with haloperidol stimulate dopamine and GABA uptake in culture of rostral mesencephalic tegmentum. Clin. Neuropharmacol. 12:1989;425-434.
63. Cash, R., Dennis, T. L., Heureux, R., Raisman, R., Javoy-Agid, F. and Scatton, B. (1987a) Parkinson's disease and dementia. Norepinephrine and dopamine in locus coeruleus. Neurology 37, 42-46.
64. 1 receptor and cyclic AMP-dependent phosphorylation in Parkinson's disease. J. Neurochem. 49, 1075-1083.
65. Castaneda E., Whishaw I. Q., Robinson T. E. Changes in striatal dopamine neurotransmission assessed by microdialysis following recovery from a bilateral 6-OHDA lesion, variation as a function of lesion size. J. Neurosci. 110:1990;1847-1854.
66. Chapman C. A., Yeomans J. S., Blaha C. D., Blackburns J. R. Increased striatal dopamine efflux follows scopolamine administered systemically or to the tegmental pedunculopontine nucleus. Neuroscience. 76:1997;177-186.
67. Charara A., Smith Y., Parent A. Glutamatergic inputs from the pedunculopontine nucleus to midbrain dopaminergic neurons in primates: Phaseolus vulgaris-leucoagglutinin anterograde labeling combined with postembedding glutamate and GABA immunohistochemistry. J. Comp. Neurol. 364:1996;254-266.
68. Cheramy A., Leviel V., Glowinski L. Dendritic release of dopamine in substantia nigra. Nature. 289:1981;537-542.
69. Cheramy A., Romo R., Godeheu G., Baruch P., Glowinski J. In vivo presynaptic control of dopamine release in the cat caudate nucleus. II. Facilitatory or inhibitory influence of L-glutamate. Neuroscience. 19:1986;1018-1090.
70. Chergui, K., Akaoka, H., Charlety, P. J., Buda, M. and Chouvet, G. (1994) Subthalamic nucleus modulates burst firing of nigral dopamine neurons via NMDA receptors. Neuroreport 5, 1185-1188.
71. Chergui K., Charlety P. J., Akaoka H., Saunier C. F., Brunet J. L., Buda M., Svensson T. H., Chouvet G. Tonic activation of NMDA receptors causes spontaneous burst discharge of rat midbrain dopamine neurons in vivo. Eur. J. Neurosci. 5:1993;137-144.
72. Chergui, K., Suaud-Chagny. M. F. and Gonon, F. (1994b) Nonlinear relationship between impulse flow, dopamine release and dopamine elimination in the rat brain in vivo. Neuroscience 67, 641-645.
73. Chesselet M. F. Presynaptic regulation of neurotransmitter release in the brain. Fact and hypothesis. Neuroscience. 12:1984;347-375.
74. Chiueh C. C., Burns R. S., Markey S. P., Jacobowitz D. M., Kopin I. J. Primate model of parkinsonism: selective lesion of nigrostriatal neurons by 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine produces an extrapyramidal syndrome in rhesus monkeys. Life Sci. 36:1985;213-218.
75. Chiueh C. C., Markey S. D., Burns R. S., Johannessen J. N., Jacobowitz D. M., Kopin I. J. Neurochemical and behavioral effects of MPTP in rat, guinea pig and monkey. Psychopharmacol. Bull. 20:1984;548-553.
76. 2 and preproenkephalin mRNAs and Fos immunoreactivity in rat striatal subregions after partial dopaminergic degeneration. Eur. J. Neurosci. 8:1996;2511-2520.
77. 2 receptor mRNA levels caused by the lesion of the nigrostriatal pathway, a quantitative in situ hybridization study. Eur. J. Neurosci. 4:1992;663-672.
78. Church W. H., Justice J. B., Neill D. B. Detecting behaviorally relevant changes in extracellular dopamine with microdialysis. Brain Res. 412:1987;397-399.
79. 2 receptor mRNA after lesion or haloperidol treatment. Eur. J. Pharmacol. 186:1990;369-371.
80. Creese I., Burt D. R., Snyder S. H. Dopamine receptor binding: enhancement accompanying lesion-induced behavioural supersensitivity. Science. 197:1977;596-598.
81. 3H-spiroperidol binding. Eur. J. Pharmacol. 56:1979;277-281.
82. Date I., Felten S. Y., Felten D. L. The nigrostriatal dopaminergic system in MPTP-treated mice shows more prominent recovery by syngeneic adrenal medullary graft than by allogeneic or xenogeneic graft. Brain Res. 545:1991;191-198.
83. DeBelleroche J., Bradford H. Presynaptic control of the synthesis and release of dopamine from striatal synaptosomes: a comparison between the effects of 5-hydroxytryptamine, acetylcholine and glutamate. J. Neurochem. 35:1980;1227-1234.
84. DeDeurwaerdere P., L'Hirondel M., Bonhomme N., Lucas G., Cheramy A., Spampinato U. Serotonin stimulation of 5-HT4 receptors indirectly enhances in vivo dopamine release in the rat striatum. J. Neurochem. 68:1997;195-203.
85. DeJong G. J., Meerwaldt J. D., Schmitz P. I. M. Factors that influence the occurrence of response variations in Parkinson's disease. Ann. Neurol. 21:1987;4-7.
86. 2 receptor within GABAergic neurons of the rat striatum. Brain Res. 746:1997;239-255.
87. DeLong M. R. Primate models of movement disorders of basal ganglia origin. Trends Neurosci. 13:1990;281-285.
88. Descarries L., Watkins K. C., Garcia S., Bosler O., Doucet G. Dual character, asynaptic and synaptic, of the dopamine innervation in adult rat neostriatum: a quantitative autoradiographic and immunocytochemical analysis. J. Comp. Neurol. 375:1996;167-186.
89. DiLoreto S., Florio T., Scarnati E. Evidence that non-NMDA receptors are involved in the excitatory pathway from the pedunculopontine region to nigrostriatal dopaminergic neurons. Exp. Brain Res. 89:1992;79-86.
90. Dravid A., Jaton A. L., Enz A., Frei P. Spontaneous recovery from motor asymmetry in adult rats with 6-OHDA induced lesion of the SN. Brain Res. 311:1984;361-365.
91. Du X., Stull N. D., Iacovitti L. Brain-derived neurotrophic factor works coordinately with partner molecules to initiate tyrosine hydroxylase expression in striatal neurons. Brain Res. 680:1995;229-233.
92. Dubach M., Schmidt R., Kunkel D., Bowden D. M., Martin R., German D. C. Primate neostriatal neurons containing tyrosine hydroxylase: immunohistochemical evidence. Neurosci. Lett. 75:1987;205-210.
93. Eberling J. L., Bankiewicz K. S., Jordan S., VanBrocklin H. F., Jagust W. J. PET studies of functional compensation in a primate model of Parkinson's disease. Neuroreport. 8:1997;2727-2733.
94. Ehringer H., Hornykiewicz O. Verteilung von Noradrenalin und Dopamin (3-Hydroxytyramin) im Gehirn des Menschen und ihr Verhalten bei Erkrankungen des extrapyramidalen Systems. Klin. Wochenschr. 38:1960;1236-1239.
95. Emerich D. F., Plone M., Francis J., Frydel B. R., Winn S. R., Lindner M. D. Allevation of behavioral deficits in aged rodents following implantation of encapsuled GDNF-producing fibroblast. Brain Res. 736:1996;99-110.
96. Ennis C., Kemp J. D., Cox B. Characterization of inhibitory 5-hydroxytryptamine receptors that modulate dopamine release in the striatum. J. Neurochem. 36:1981;1515-1520.
97. 3H-monoamines from field-stimulated rat brain slices. Acta Physiol. Scand. Suppl. 371:1971;35-44.
98. Fiancada M. S., Kordower J. H., Hansen J. T., Jiao S. S., Gash D. M. Adrenal medullary autografts into the basal ganglia of Cebus monkeys: injury-induced regeneration. Exp. Neurol. 102:1988;76-91.
99. Fiedler J., Bustos G. Cortical ablation reduces veratridine-evoked release of endogenous glutamate from superfused nigral slices. Neurosci. Lett. 22:1991;96-98.
100. Flaherty A. W., Graybiel A. M. Output architecture of the primate putamen. J. Neurosci. 13:1993;3222-3237.
101. Foix, C. and Nicolesco, J. (1925). L'anatomie pathologique de la maladie de Parkinson. Masson, Paris.
102. Francis J. W., Visger J. V., Markelonis J., Oh T. H. Neuroglial responses to the dopaminergic neurotoxicant 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine in mouse striatum. Neurotoxicol. Teratol. 17:1995;7-12.
103. Freeman A. S., Meltzer L. T., Bunney B. S. Firing properties of substantia nigra dopaminergic neurons in freely moving rats. Life Sci. 36:1985;1983-1994.
104. Freund T. F., Powell J. F., Smith A. D. Tyrosine-hydroxylase-immunoreactive boutons in synaptic contact with identified striatonigral neurons, with particular reference to dendritic spines. Neuroscience. 13:1985;1189-1215.
105. Frohna P. A., Neal-Beliveau B. S., Joyce J. N. Delayed plasticity of the mesolimbic dopamine system following neonatal 6-OHDA lesions. Synapse. 25:1997;293-305.
106. Futami T., Takakusaki K., Kita S. T. Glutamatergic and cholinergic inputs from the pedunculopontine tegmental nucleus to dopamine neurons in the substantia nigra pars compacta. Neurosci. Res. 21:1995;331-342.
107. Fuxe, K. and Agnati, L. F. (1991). Two principal modes of electrochemical communication in the brain: volume versus wiring transmission. In Volume transmission in the brain: novel mechanisms for neural transmission (Eds K. Fuxe, and L. F. Agnati), Vol. 1, pp. 1-9. Raven Press, New York.
108. Garcia-Munoz M., Patino P., Young S. J., Groves P. M. Effect of nicotine on dopaminergic nigrostriatal axons requires stimulation of presynaptic glutamatergic receptors. J. Pharmacol. Exp. Ther. 277:1996;1685-1693.
109. Garris P. A., Ciolkowski E. L., Pastore P., Wightman R. M. Efflux of dopamine from the synaptic cleft in the nucleus accumbens of the rat brain. J. Neurosci. 14:1994;6084-6093.
110. Garris P. A., Walker Q. D., Wightman R. M. Dopamine release and uptake rates both decrease in the partially denervated striatum in proportion to the loss of dopamine terminals. Brain Res. 753:1997;225-234.
111. Garris P. A., Wightman R. M. Different kinetics govern dopaminergic transmission in the amygdala, prefrontal cortex, and striatum: an in vivo voltammetric study. J. Neurosci. 14:1994;442-450.
112. Gash D. M., Zhang Z., Cass W. A., Ovadia A., Simmerman L., Martin D., Russell D., Collins F., Hoffer B. J., Gerhardt G. A. Morphological and functional effects of intranigrally administered GDNF in normal rhesus monkeys. J. Comp. Neurol. 363:1995;345-358.
113. Gash D. M., Zhang Z., Ovadia A., Cass W. A., Yi A., Simmerman L., Russell D., Martin D., Lapchak P. A., Collins F., Hoffer B. J., Gerhardt G. A. Functional recovery in parkinsonian monkey treated with GDNF. Nature. 380:1996;252-255.
114. Gaspar P., Febvret A., Colombo J. Serotoninergic sprouting in primate MPTP-induced hemiparkinsonism. Exp. Brain Res. 96:1993;100-106.
115. Gauchy C., Desban M., Krebs M. O., Glowinski J., Kemel M. L. Role of dynorphin-containing neurons in the presynaptic inhibitory control of the acetylcholine-evoked release of dopamine in the striosomes and the matrix of the cat caudate nucleus. Neuroscience. 41:1991;449-458.
116. Geffen L. B., Jessel T. M., Cuello A. C., Iversen L. L. Release of dopamine from dendrites in substantia nigra. Nature. 260:1976;258-260.
117. Gerfen C. R. The neostriatal mosaic: compartimentalization of corticostriatal input and striatonigral output systems. Nature. 311:1984;461-464.
118. 2 dopamine receptor-regulated gene expression of striatonigral and striatopallidal neurons. Science. 250:1990;1429-1432.
119. Gerlach M., Riederer P. Animal models of Parkinson's disease: an empirical comparison with the phenomenology of the disease in man. J. Neural Transm. 103:1996;987-1041.
120. Girault J. A., Raisman R., Agid Y., Greengard P. Striatal phosphoproteins in Parkinson's disease and progressive supranuclear palsy P. Natl. Acad. Sci. USA. 86:1989;2493-2497.
121. Giros B., Jaber M., Jones S. R., Wightman R. M., Caron M. G. Hyperlocomotion and indifference to cocaine and amphetamine in mice lacking the dopamine transporter. Nature. 379:1996;606-612.
122. Glowinski J., Cheramy A., Romo R., Barbeito L. Presynaptic regulation of dopaminergic transmission in the striatum. Cell. Mol. Neurobiol. 8:1988;7-17.
123. Gnanalingham K. K., Milkowski N. A., Smith L. A., Hunter A. J., Jenner P., Marsden C. D. Short- and long-term changes in striatal and extrastriatal dopamine uptake sites in the MPTP-treated common marmoset. Eur. J. Pharmacol. 277:1995;235-241.
124. Goetz G. G. Dopaminergic agonists in the treatment of Parkinson's disease. Neurology. 46:1990;50-57.
125. Gomez-Mancilla B., Bedard P. J. Effect of nondopaminergic drugs on L-DOPA-induced dyskinesia in MPTP-treated monkeys. Clin. Neuropharmacol. 16:1993;418-427.
126. 1 receptors in the rat striatum in vivo. J. Neurosci. 17:1997;5972-5978.
127. Gonon F. G. Nonlinear relationship between impulse flow and dopamine released by rat midbrain dopaminergic neurons as studied by in vivo electrochemistry. Neuroscience. 24:1988;19-28.
128. Gonon F. G., Buda M. J. Regulation of dopamine release by impulse flow and by autoreceptors as studies by in vivo voltammetry in the rat striatum. Neuroscience. 14:1985;765-774.
129. Grace, A. A. (1987). The regulation of dopamine neuron activity as determined by in vivo and in vitro intracellular recordings. In Neurophysiology of dopaminergic systems - current status and clinical perspectives (Eds L. A. Chiodo, and A. S. Freeman), pp. 1-66. Lakeshore, Detroit.
130. Grace, A. A. and Bunney, B. S. (1984a) The control of firing pattern in nigral dopamine neurons: burst firing. J. Neurosci. 4, 2877-2890.
131. Grace, A. A. and Bunney, B. S. (1984b) The control of firing pattern in nigral dopamine neurons: single spike firing. J. Neurosci. 4, 2866-2876.
132. Grace A. A., Bunney B. S. Opposing effects of striatonigral feedback pathways on midbrain dopaminergic cell activity. Brain Res. 333:1985;271-284.
133. Grace A. A., Onn S.-P. Morphology and electrophysiological properties of immunochemically identified rat dopamine neurons recorded in vitro. J. Neurosci. 9:1989;3463-3481.
134. Grillner, P., Bonci, A., Svensson, T. H., Bernardi, G. and Mercuri, N. B. (1997). Muscarinic agonists depress excitatory synaptic transmission to the dopamine neurons in the ventral mesencephalon. Paper presented at the Soc. Neurosci. Abstr., New Orleans.
135. Grofova I. Identification of striatal and pallidal neurons projecting to substantia nigra. An experimental study by means of retrograde transport of horseradish peroxydase. Brain Res. 91:1975;286-291.
136. Gross, C., Bezard, E., Boraud, T. and Bioulac, B. (1996a). Compensatory effects of glutamatergic inputs to the SNc in MPTP-treated monkeys. Paper presented at the Soc. Neurosci. Abstr., Washington.
137. Gross, C., Bezard, E., Boraud, T. and Bioulac, B. (1996b). Glutamate, a new approach to the physiopathology and treatment of Parkinson's disease. Arch. Physiol. Biochem. 104, 35.
138. Gross C., Rougier A., Guehl D., Boraud T., Julien J., Bioulac B. High frequency stimulation of the Globus Pallidus internalis in Parkinson's disease: a 7 case study. J. Neurosurg. 87:1997;491-498.
139. Groves P. M., Linder J. C., Young S. J. 5-hydroxydopamine-labeled dopaminergic axons: three-dimensional reconstructions of axons, synapses and postsynaptic targets in rat neostriatum. Neuroscience. 58:1994;593-604.
140. Groves P. M., Wilson C. J., Young S. J., Rebec G. V. Self-inhibition by dopaminergic neurons. Science. 190:1975;522-529.
141. Groves P. M., Young S. J., Wilson C. J. Self-inhibition by dopaminergic neurons: disruption by (±)-a-methyl-p-tyrosine pretreatment or anterior diencephalic lesions. Neuropharmacol. 15:1976;755-762.
142. Guiorguieff, M. F., Floc'h, M. L. L. and Glowinski, J. (1977a). Involvement of cholinergic presynaptic receptors of nicotinic and muscarinic types in the control of the spontaneous release of dopamine from striatal dopaminergic terminals in the rat. J. Pharmacol. Exp. Ther. 200, 535-544.
143. Guiorguieff, M. F., Kemel, M. L. and Glowinski, J. (1977b). Presynaptic effect of L-glutamic acid on the release of dopamine in rat striatal slices. Neurosci. Lett. 6, 73-77.
144. Guridi J., Herrero M. T., Luquin M. R., Guillen J., Ruberg M., Laguna J., Vila M., Javoy-Agid F., Agid Y., Hirsch E., Obeso J. A. Subthalamotomy in parkinsonian monkeys. Brain. 119:1996;1717-1727.
145. Hadjiconstantinou M., Mariani A. P., Neff N. H. GM1 ganglioside-induced recovery of nigrostriatal dopaminergic neurons after MPTP: an immunohistochemical study. Brain Res. 484:1989;297-303.
146. Hadjiconstantinou M., Rossetti M., paxton R. C., Neff N. H. Administration of GM1 ganglioside restores the dopamine content in striatum after chronic treatment with MPTP. Neuropharmacology. 25:1986;1075-1077.
147. Halliday G. M., Li Y. W., Blumbergs P. C., Joh T. H., Cotton R. G. H., Howe P. R. C., Blessing W. W., Geffen L. B. Neuropathology of immunohistochemically identified brainstem neurons in Parkinson's disease. Ann. Neurol. 27:1990;373-385.
148. Hantraye P., Khalili-Varastesh M., Peschanski M., Mazière M. MPTP: mécanismes biologiques et limites d'un modèle expérimental de la maladie de Parkinson. Circul. Métabol. Cerv. 7:1990;5-19.
149. Hassani O. K., Mouroux M., Feger J. Increased subthalamic neuronal activity after nigral dopaminergic lesion independent of disinhibition via the globus pallidus. Neuroscience. 72:1996;105-115.
150. Hassler R. Zur Normal Anatomie der Substantia Nigra. Versuch einer architektonischen Gliederung. J. Psychol. Neurol. 48:1937;1-55.
151. Hassler R. Zur Pathologie der Paralysis Agitans und des postenzephalitischen Parkinsonismus. J. Psychol. Neurol. 48:1938;387-476.
152. Heffner T. G., Zigmond M. J., Stricker E. M. Effects of dopaminergic agonists and antagonists on feeding in intact and 6-hydroxydopamine-treated rats. J. Pharmacol. Exp. Ther. 201:1977;386-399.
153. Hefti F., Enz A., Melamed E. Partial lesions of the nigrostriatal pathway in the rat. Acceleration of transmitter synthesis and release of surviving dopaminergic neurons by drugs. Neuropharmacol. 24:1985;19-23.
154. Hefti F., Melamed E., Wurtman R. J. Partial lesions of the dopaminergic nigrostriatal system in rat brain: biochemical characterization. Brain Res. 195:1980;123-137.
155. Helmreich I., Reimann W., Hertting G., Starke K. Are presynaptic dopamine autoreceptors and postsynaptic dopamine receptors in the rabbit caudate nucleus pharmacologically different? Neuroscience. 7:1982;1559-1566.
156. Hemmings H. C., Nairn A. C., Aswaad D. W., Greengard P. DARP-32, a dopamine and adenosine 3′-5′-monophosphate-regulated phosphoprotein enriched in dopamine innervated brain regions. II. Purification and characterization of the phosphoprotein from bovine caudate nucleus. J. Neurosci. 4:1984;99-110.
157. Herkenham, M. (1991). Mismatches between neurotransmitter and receptor localizations: implications for endocrine functions in brain. In Volume transmission in the brain: novel mechanisms for neural transmission (Eds K. Fuxe, and L. F. Agnati), Vol. 1, pp. 63-87. Raven Press, New York.
158. Hernández-Lopez S., Gongora-Alfaro J. L., Martinez-Fong D., Aceves J. A cholinergic input to the substantia nigra pars compacta increases striatal dopamine metabolism measured by in vivo voltammetry. Brain Res. 598:1992;114-120.
159. Herrero M. T., Perez-Otano I., Hirsch E. C., Agid Y., Luquin M. R., Obeso J. A., DelRio J. GM1 ganglioside promotes the recovery of surviving midbrain dopaminergic neurons in MPTP-treated monkeys. Neuroscience. 56:1993;965-972.
160. 2 dopamine receptor proteins in the dorsal striatum and their synaptic relationships with motor corticostriatal afferents. J. Neurosci. 15:1995;5222-5237.
161. Hirsch E. C., Duyckaerts C., Javoy-Agid F., Hauw J. J., Agid Y. Does adrenal graft enhance recovery of dopaminergic neurons in Parkinson's disease? Ann. Neurol. 27:1990;676-682.
162. Hirsch E. C., Graybiel A. M., Agid Y. Melanized dopaminergic neurons are differentially affected in Parkinson's disease. Nature. 334:1988;345-348.
163. Hoffmann I. S., Cebeddu L. X. Rate and duration of stimulation determine presynaptic effects of haloperidol on dopaminergic neurons. J. Neurochem. 39:1982;585-588.
164. Hollerman, J. R., Berger, T. W. and Grace, A. A. (1986). Compensatory changes in the activity of nigral dopamine cells in response to partial dopamine depleting lesions. Paper presented at the Soc. Neurosci. Abstr., Washington.
165. Hollerman, J. R. and Grace, A. A. (1988). Nigral DA cell recruitment as a compensatory mechanism. Paper presented at the Soc. Neurosci. Abstr., Toronto.
166. Hollerman J. R., Grace A. A. The effects of dopamine-depleting brain lesions on the electrophysiological activity of rat substantia nigra dopamine neurons. Brain Res. 533:1990;203-212.
167. Hollerman J. R., Grace A. A. Subthalamus nucleus cell firing in the 6-OHDA-treated rat: basal activity and response to haloperidol. Brain Res. 590:1992;291-299.
168. Hornykiewicz C. Dopamine and brain function. Pharmacol. Rev.
169. Hornykiewicz, O. (1979). Compensatory biochemical changes at the striatal dopamine synapse in Parkinson's disease - limitation in L-dopa therapy. In Advances in neurology, pp. 275-281. Raven Press, New York.
170. Hornykiewicz, O. (1993). Parkinson's disease and the adaptative capacity of the nigrostriatal dopamine system: possible neurochemical mechanisms. In Advances in neurology (Eds H. Narabayashi, N. Nagatsu, N. Yanagisawa, and Y. Mizuno), Vol. 60, pp. 140-147. Raven Press, New York.
171. Howells D. W., Donnan G. A., Wong J. Y. F., Kaczmarczyk S. J., Chilcho P. J., Fabinyi G. C., Mendelsohn F. A. O. Surgical damage stimulates proliferation of dopamine uptake sites in normal mouse brain. Brain Res. 622:1993;285-288.
172. Howells D. W., Liberatore G. T., Wong J. Y. F., Donnan G. A. Dopaminergic responses to striatal damage. J. Neurol. Sci. 139:1996;125-130.
173. 2 dopaminergic receptors mediate inhibition of excitatory synaptic transmission in rat neostriatum. Brain Res. 690:1995;264-268.
174. Hyman C., Hofer M., Barde Y.-A., Juhasz M., Yancopoulos G. D., Squinto S. P., Lindsay R. M. BDNF is a neurotrophic factor for dopaminergic neurons of the substantia nigra. Nature. 350:1991;230-232.
175. Iacovitti L. Effects of a novel differentiation factor on the development of catecholamine traits in noncatecholamine neurons from various regions of the rat brain: studies in tissue culture. J. Neurosci. 11:1991;2403-2409.
176. Ikemoto K., Kitahama K., Jouvet A., Arai R., Nishimura A., Nishi K., Nagatsu I. Demonstration of L-dopa decarboxylating neurons specific to human striatum. Neurosci. Lett. 232:1997;111-114.
177. Ingham, C. A., Hood, S. H. and Arbuthnott, G. W. (1991). A light and electron microscopical study of enkephalin-like immunoreactive structures in the rat neostriatum after removal of the nigrostriatal dopaminergic pathway. Neuroscience 42 (715-730).
178. Ingham C. A., Hood S. H., VanMaldegem B., Weeninck A., Arbuthnott G. W. Morphological changes in the rat neostriatum after unilateral 6-hydroxydopamine injections into the nigrostriatal pathway. Exp. Brain Res. 93:1993;17-27.
179. Isacson O., Deacon T. Neural transplantation studies reveal the brain's capacity for continuous reconstruction. Trends Neurosci. 20:1997;477-482.
180. Iversen, S. D. and Creese, I. (1975). Behavioral correlates of dopaminergic supersensitivity. In Advances in neurology (Eds D. B. Calne, T. N. Chase, and A. Barbeau), Vol. 9, pp. 81-92. Raven Press, New York.
181. Jaber M., Jones S., Giros B., Caron M. G. The dopamine transporter: a crucial component regulating dopamine transmission. Mov. Disord. 12:1997;629-633.
182. Jaber, M., Jones, S. R., Bosse, R., Giros, B. and Caron, M. G. (1996). Dramatic regulation of tyrosine hydroxylase in the basal ganglia of mice lacking the dopamine transporter. Paper presented at the Soc. Neurosci. Abstr., Washington.
183. Jackson A., Crossman A. R. Nucleus tegmenti pedunculopontinus efferent connections with special reference to the basal ganglia, studied in the rat by anterograde and retrograde transport of horseradish peroxidase. Neuroscience. 10:1983;725-765.
184. Janson, A. M. and Zhao, M. (1997). Time course study of the total number of nestin immunoreactive cells in substantia nigra after an MPTP-induced lesion in C57/BL6 mouse. Paper presented at the Soc. Neurosci. Abstr., New Orleans.
185. Javoy-Agid F., Hirsch E. C., Dumas S., Duyckaerts C., Mallet J., Agid Y. Decreased tyrosine hydroxylase messenger RNA in the surviving dopamine neurons of the substantia nigra in Parkinson's disease: an in situ hybridization study. Neuroscience. 38:1990;245-253.
186. Javoy-Agid F., Ruberg M., Pique L., Bertagna X., Taquet H., Studler J. M., Cesselin F., Epelbaum J., Agid Y. Biochemistry of the hypothalamus in Parkinson's disease. Neurology. 34:1984;672-675.
187. Jellinger K. Pathologic correlates of dementia in Parkinson's disease. Arch. Neurol. 44:1987;690.
188. Jimenez-Castellanos J., Graybiel A. M. Compartmental origins of striatal efferent projections in the cat. Neuroscience. 32:1989;297-321.
189. Jonsson G., Gorio A., Hallman H., Kojima H., Janigro D., Luthman J., Zanoni R. Effects of GM1 ganglioside on developing and mature serotonin and noradrenaline neurons lesioned by selective neurotoxins. J. Neurosci. Res. 12:1984;459-476.
190. Joyce J. N., Frohna P. S., Neal-Beliveau B. S. Functional and molecular differentiation of the dopamine system induced by neonatal denervation. Neurosci. Biobehav. Rev. 20:1996;453-486.
191. Kandel E. R., Spencer W. A. Electrophysiology of hippocampal neurons. II. After-potentials and repetitive firing. J. Neurophysiol. 24:1961;243-259.
192. Kaplan M. S. Plasticity after brain lesions: contemporary concepts. Arch. Phys. Med. Rehabil. 69:1988;984-991.
193. Kastner A., Hirsch E. C., Agid Y., Javoy-Agid F. Tyrosine hydroxylase protein and messenger RNA in the dopaminergic nigral neurons of patients with Parkinson's disease. Brain Res. 606:1993;341-345.
194. Kastner A., Hirsch E. C., Herrero M. T., Javoy-Agid F., Agid Y. Immunocytochemical quantification of tyrosine hydroxylase at a cellular level in the mesencephalon of control subjects and patients with Parkinson's and Alzheimer's disease. J. Neurochem. 61:1993;1024-1034.
195. Kawagoe K. T., Garris P. A., Wiedmann D. J., Wightman R. M. Regulation of transient dopamine concentration gradients in the microenvironment surrounding nerve terminals in the rat striatum. Neuroscience. 51:1992;55-64.
196. Keefe K. A., Zigmond M. J., Abercrombie E. D. Extracellular dopamine in striatum: influence of nerve impulse activity in medial forebrain bundle and local glutamatergic input. Neuroscience. 47:1992;325-332.
197. 2 receptors in striatum. J. Neurochem. 49:1987;115-120.
198. Kemel M. L., Desban M., Glowinski J., Gauchy C. Functional heterogeneity of the matrix compartment in the cat caudate nucleus as demonstrated by the cholinergic presynaptic regulation of dopamine release. Neuroscience. 50:1992;597-610.
199. Kingdom P. s. D. R. G. i. t. U. Comparisons of therapeutic effects of levodopa, levodopa and selegiline, and bromocriptine in patients with early, mild Parkinson's disease: three year interim report. Br. Med. J. 307:1993;469-472.
200. Kingdom P. s. D. R. G. i. t. U. Comparisons of therapeutic effects and mortality data of levodopa and levodopa combined with selegiline in patients with early, mild Parkinson's disease. Br. Med. J. 311:1995;1602-1607.
201. Kita H., Kita S. T. Efferent projections of the subthalamic nucleus in the rat: light and electron microscopic analysis with the PHA-L method. J. Comp. Neurol. 260:1987;435-452.
202. Kita T., Kita H., Kitaò S. T. Electrical membrane properties of rat substantia nigra pars compacta neurons in an in vitro slice preparation. Brain Res. 372:1986;21-30.
203. Kobayashi K., Kaneda N., Ichinose H., Kishi F., Nakazawa A., Kurosawa Y., Fujita K., Nagatsu T. Structure of the human tyrosine hydroxylase gene: alternative splicing from a single gene accounts for generation of four mRNA types. J. Biochem. 103:1988;907-912.
204. Kojima J., Yamaji Y., Matsumura M., Nambu A., Inase M., Tokuno H., Takada M., Imai H. Excitotoxic lesions of the pedunculopontine tegmental nucleus produce contralateral hemiparkinsonism in the monkey. Neurosci. Lett. 226:1997;111-114.
205. Komori K., Fujii T., Karasawa N., Yamada K., Nagatsu I. Some neurons of the mouse cortex and caudoputamen contain aromatic L-amino acid decarboxylase but not monoamines. Acta Histochem. Cytochem. 24:1991;571-577.
206. Kornhuber J., Jin-Soo K., Kornhuber M. E., Kornhuber H. H. The corticonigral projection: reduced glutamate content in the substantia nigra following frontal cortex ablation in the rat. Brain Res. 322:1984;124-126.
207. Kurlan, R., Kim, M. H. and Gash, D. M. (1991a) Oral levodopa dose-response study in MPTP-induced hemiparkinsonian monkeys: assessment with a new rating scale for monkey parkinsonism. Mov. Disord. 6, 111-118.
208. Kurlan, R., Kim, M. H. and Gash, D. M. (1991b) The time-course and magnitude of spontaneous recovery of parkinsonism produced by intracarotid administration of MPTP to monkeys. Ann. Neurol. 26, 677-679.
209. 2 receptors to increase potassium conductance in neurones of the rat substantia nigra zona compacta. J. Physiol. (Lond.). 392:1987;397-416.
210. Laitinen L. V., Bergenheim A. T., Hariz M. I. Leksell's posteroventral pallidotomy in the treatment of Parkinson's disease. J. Neurosurg. 76:1992;53-61.
211. Langston J. W., Forno L. S., Rebert C. S., Irwin I. Selective nigral toxicity after systemic administration of 1-methyl-4-phenyl 1-1,2,3,6, tetrahydropyridine (MPTP) in the squirrel monkey. Brain Res. 292:1984;390-394.
212. Lapchak P. A., Miller P. J., Jiao S., Araujo D. M., Hilt D., Collins F. Biology of glial cell line-derived neurotrophic factor (GDNF): Implications for the use of GDNF to treat Parkinson's disease. Neurodegeneration. 5:1996;197-205.
213. Lavoie B., Parent A. Pedunculopontine nucleus in the squirrel monkey: cholinergic and glutamatergic projections to the substantia nigra. J. Comp. Neurol. 344:1994;232-241.
214. Lee C. S., Schulzer M., Mak E. K., Snow B. J., Tsui J. K., Calne S., Hammerstad J., Calne D. B. Clinical observations on the rate of progression of idiopathic parkinsonism. Brain. 117:1994;501-507.
215. Lee H.-J., Alcorn L. M., Weiler M. H. Effects of various experimental manipulations on neostriatal acetylcholine and dopamine release. Neurochem. Res. 16:1991;875-883.
216. Lee T., Seeman P., Rajput A., Farley I. J., Hornykiewicz O. Receptor basis for dopaminergic supersensitivity in Parkinson's disease. Nature. 273:1978;150-151.
217. Lees A. J. Levodopa substitution: the gold standard. Clin. Neuropharmacol. 17:1994;S1-S6.
218. Lees G. J. Therapeutic potential of AMPA receptor ligand in neurological disorders. CNS Drugs. 5:1996;51-74.
219. Lees G. J., Stern G. M. Sustained low-dose levodopa therapy in Parkinson's disease: a 3-year follow-up. Adv. Neurol. 37:1983;9-15.
220. Lesser R. P., Fahn S., Snider S. R., Cote L. J., Isgreen W. P., Barrett R. E. Analysis of the clinical problems in parkinsonism and the complications of long-term levodopa therapy. Neurology. 19:1979;1253-1260.
221. 2 dopamine receptors in brain with subtype-specific antibodies P. Natl. Acad. Sci. USA. 90:1993;8861-8865.
222. Leviel V., Gobert A., Guibert B. The glutamate-mediated release of dopamine in the rat striatum: further characterization of the dual excitatory-inhibitory function. Neuroscience. 39:1990;305-312.
223. Levy R., Herrero M.-T., Ruberg M., Villares J., Faucheux B., Guridi J., Guillen J., Luquin M. R., Javoy-Agid F., Obeso J. A., Agid Y., Hirsch E. C. Effects of nigrostriatal denervation and L-Dopa therapy on the GABAergic neurons of the striatum in MPTP-treated monkeys and Parkinson's disease: an in situ hybridization study of GAD67-mRNA. Eur. J. Neurosci. 7:1995;1199-1209.
224. Levy R., Vila M., Herrero M.-T., Faucheux B., Agid Y., Hirsch E. C. Striatal expression of substance P and methionine-enkephalin genes in patients with Parkinson's disease. Neurosci. Lett. 199:1995;220-224.
225. Lewis D. A., Melchitzky D. S., Haycock J. W. Expression and distribution of two isoforms of tyrosine hydroxylase in macaque monkey brain. Brain Res. 656:1994;1-13.
226. Li Y. X., Bertram R., Rinzel J. Modeling NMDA-induced bursting in dopamine neurons. Neuroscience. 71:1996;397-410.
227. Liberatore G. T., Wong J. Y. F., Porritt M. J., Donnan G. A., Howells D. W. Expression of glial cell line-derived neurotrophic factor (GDNF) mRNA following mechanical injury to mouse striatum. Neuroreport. 8:1997;3097-3101.
228. Lieberman A. N., Goldstein M. Bromocriptine in Parkinson's disease. Pharmacol. Rev. 37:1985;217-227.
229. Ling, Z. D. and Carvey, P. M. (1997). Mesencephalic progenitor cells exposed to cytokines become enriched in dopamine neurons. Paper presented at the Soc. Neurosci. Abstr., New Orleans.
230. Llinas R., Greenfield S. A., Jahnsen H. Electrophysiology of pars compacta cells in the in vitro substantia nigra-a possible mechanism for dendritic release. Brain Res. 294:1984;127-132.
231. Llinas R., Jahnsen H. Electrophysiology of mammalian thalamic neurones in vitro. Nature. 297:1982;406-408.
232. Lloyd K. G., Davidson L., Hornykiewicz O. The neurochemistry of Parkinson's disease: effects of L-DOPA therapy. J. Pharmacol. Exp. Ther. 195:1975;453-464.
233. Lozano A. M., Lang A. E., Galvez-Jimenez N., Miyasaky J., Duff J., Hutchison W. D., Dostrovsky J. O. Effect of GPi pallidotomy on motor function in Parkinson's disease. Lancet. 346:1995;1383-1387.
234. Lundberg C., Martinez-Serrano A., Cattaneo E., McKay R. D. G., BjÜrklund A. Survival, integration and differentiation of neural stem cell lines after transplantation to the adult rat striatum. Exp. Neurol. 145:1997;342-360.
235. Manley L. D., Kuczenski R., Segal D. S., Young S. J., Groves P. M. Effects of frequency and pattern of medial forebrain bundle stimulation on caudate dialysate dopamine and serotonin. J. Neurochem. 58:1992;1491-1498.
236. Marsden, C. D., Parkes, J. D. and Quinn, N. (1982). Fluctuations of disability in Parkinson's disease - clinical aspects. In Movement disorders (Eds C. D. Marsden, and S. Fahn), pp. 96-122. Butterworth, London.
237. Marshall J. F. Somatosensory inattention after dopamine-depleting intracerebral 6-OHDA injections: spontaneous recovery and pharmacological control. Brain Res. 177:1979;311-324.
238. 1 binding density following mesotelencephalic 6-hydroxydopamine injections: an autoradiographic analysis. Brain Res. 493:1989;247-257.
239. Martin D., Miller G., Cullen T., Fisher N., Dix D., Russell D. Intranigral or intrastriatal injections of GDNF: effects on monoamine levels and behavior in rats. Eur. J. Pharmacol. 317:1996;247-256.
240. Masserano J. M., Weiner N. Tyrosine hydroxylase regulation in the central nervous system. Mol. Cell. Biochem. 54:1983;129-152.
241. Matsumura M., Kojima J., Yamaji Y., Imai H., Takada M., Tokuno H., Nambu A., Inase M. Hemiparkinsonism in macaque monkeys produced by lesioning the pedunculopontine tegmental nucleus. Mov. Disord. 12(Suppl. 1):1997;94.
242. 1 receptor stimulation in the subthalamic nucleus after unilateral 6-OHDA lesions of the substantia nigra pars compacta. Paper presented at the Soc. Neurosci. Abstr., New Orleans.
243. Mercuri, N. B., Bonci, A., Siniscalchi, A., Stefani, A., Calabresi P. and Bernardi, G. (1996a) Electrophysiological effects of monoamine oxydase inhibition on rat midbrain dopaminergic neurones: an in vitro study. Br. J. Pharmacol. 117, 528-532.
244. Mercuri, N. B., Grillner, P. and Bernardi, G. (1996b) NMDA receptors mediate a slow excitatory postsynaptic potential in the rat midbrain dopaminergic neurons. Neuroscience 74, 785-792.
245. Mileson B. E., Lewis M. H., Mailman R. B. Dopamine receptor 'supersensitivity' occurring without receptor up-regulation. Brain res. 561:1991;1-10.
246. Miller, W. C. and Long, M. R. D. (1987). Altered tonic activity of neurons in the globus pallidus and subthalamic nucleus in the primate MPTP model of parkinsonism. In Basal Ganglia II (Eds M. B. Carpenter, and A. Jayaraman), Vol. 32, pp. 415-427. Plenum Press, New York.
247. Mintz, I. M., Barstow, K. L. and Deeter, C. (1997). Direct subthalamic input to dopaminergic neurons in the rat substantia nigra. Paper presented at the Soc. Neurosci. Abstr., New Orleans.
248. Mishra R. K., Marshall A. M., Katzman R., Nakman M. H. Enhancement of dopamine-stimulated adenylate cyclase activity in rat caudate after lesions in the substantia nigra: evidence for denervation supersensitivity P. Natl. Acad. Sci. USA. 71:1974;3883-3888.
249. Mitchell I. J., Clarke C. E., Boyce S., Robertson R. G., Peggs D., Sambrook M. A., Crossman A. R. Neural mechanisms underlying parkinsonian symptoms based upon regional uptake of 2-deoxyglucose in monkeys exposed to 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine. Neuroscience. 32:1989;213-226.
250. Mogi M., Harada M., Kiuchi K., Kojima K., Kondo T., Narabayashi H., Raush D., Riederer P., Jellinger K., Nagatsu T. Homospecific activity (activity per enzyme protein) of tyrosine hydroxylase increases in parkinsonian brain. J. Neural Transm. 72:1988;77-82.
251. 2 dopamine receptor mRNA in the brains of monkeys lesioned with MPTP: correction with chronic administration of L-3,4-dihydroxyphenylalanine. J. Pharmacol. Exp. Ther. 50:1996;1073-1079.
252. 18F]dopa-PET and clinical study of the rate of progression in Parkinson's disease. Brain. 119:1996;585-591.
253. Mura A., Jackson D., Manley M. S., Young S. J., Groves P. M. Aromatic L-amino acid decarboxylase immunoreactive cells in the rat striatum: a possible site for the conversion of exogenous L-Dopa to dopamine. Brain Res. 704:1995;51-60.
254. Nicholson, C. and Rice, M. E. (1990). Diffusion of ions and transmitters in the brain cell microenvironment. In Volume transmission in the brain: Novel mechanisms for neural transmission (Eds K. Fuxe, and L. F. Agnati), Vol. 1, pp. 279-294. Raven Press, New York.
255. Nieoullon A., Cheramy A., Glowinski J. Release of dopamine evoked by electrical stimulation of the motor and visual areas of the cerebral cortex in both caudate nuclei and in the substantia nigra in the cat. Brain Res. 145:1978;69-83.
256. Niijima K., Yoshida M. Activation of mesencephalic dopamine neurons by chemical stimulation of the nucleus tegmenti pedunculopontinus pars compacta. Brain Res. 451:1988;163-171.
257. Nirenberg M. J., Vaughan R. A., Uhl G. R., Kuhar M. J., Pickel V. M. The dopamine transporter is localized to dendritic and axonal plasma membranes of nigrostriatal dopaminergic neurons. J. Neurosci. 16:1996;436-447.
258. Nisembaum E. S., Stricker E. M., Zigmond M. J., Berger T. W. Long-term effects of dopamine-depleting brain lesions on spontaneous activity of type II striatal neurons: relation to behavioral recovery. Brain Res. 398:1986;221-230.
259. Nisembaum E. S., Stricker E. M., Zigmond M. J., Berger T. W. Spontaneous activity of type II but not type I striatal neurons is correlated with recovery of behavioral function after dopamine-depleting brain lesions. Brain Res. 473:1988;389-393.
260. Nissbrandt H., Elverfors A., Engberg G. Pharmacologically induced cessation of burst activity in nigral dopamine neurons: significance for the terminal dopamine efflux. Synapse. 17:1994;217-224.
261. Ogura, M., Nakao, N., Nakai, E., Nakai, K. and Itakura, T. (1997). The firing activity of the pedunculopontine nucleus and basal ganglia in 6-OHDA lesioned rats. Paper presented at the Soc. Neurosci. Abstr., New Orleans.
262. Olanow C. W. A rationale for monoamine oxidase inhibition as neuroprotective therapy for Parkinson's disease. Mov. Disord. 8:1993;81-87.
263. Onn S.-P., Berger T. W., Stricker E. M., Zigmond M. J. Effects of intraventricular 6-hydroxydopamine on the dopaminergic innervation of striatum: histochemical and neurochemical analysis. Brain Res. 376:1986;8-19.
264. Orr W. B., Gardiner T. W., Stricker E. M., Zigmond M. J., Berger T. W. Short-term effects of dopamine-depleting brain lesions on spontaneous activity of striatal neurons: relation to local dopamine concentration and behavior. Brain Res. 376:1986;20-28.
265. Otto D., Unsicker K. Basic FGF reverses chemical and morphological deficits in the nigrostriatal system of MPTP-treated mice. J. Neurosci. 10:1990;1912-1921.
266. Overton P., Clark D. Iontophoretically administered drugs acting at the NMDA receptor modulate burst firing in A9 dopamine neurons in the rat. Synapse. 10:1992;131-140.
267. Overton P. G., O'Callaghan J. F. X., Greenfield S. A. Possible intermixing of neurons from the subthalamic nucleus and substantia nigra pars compacta in the guinea-pig. Exp. Brain Res. 107:1995;151-165.
268. Overton P. G., Tong Z.-Y., Clark D. A pharmacological analysis of the burst events induced in midbrain dopaminergic neurons by electrical stimulation of the prefrontal cortex in the rat. J. Neural Transm. 103:1996;523-540.
269. Page R. D., Sambrook M. A., Crossman A. R. Thalamotomy for the alleviation of levodopa-induced dyskinesia: experimental studies in the MPTP-treated parkinsonian monkey. Neuroscience. 55:1993;147-165.
270. Pakkenberg B., Moller A., Gundersen H. J. G., Dam A. M., Pakkenberg H. The absolute number of nerve cells in substantia nigra in normal subjects and in patients with Parkinson's disease estimated with an unbiased stereological method. J. Neurol. Neurosurg. Ps. 54:1991;30-33.
271. Parent A., Cote P. Y., Lavoie B. Chemical anatomy of primate basal ganglia. Prog. Neurobiol. 46:1995;131-197.
272. Parent A., Hazrati L. N. Functional anatomy of the basal ganglia. II. The place of subthalamic nucleus and external pallidum in basal ganglia circuitry. Brain Res. Rev. 20:1995;128-154.
273. Parkinson, J. (1817). An essay on the shaking palsy. Sherwood, Nelly and Jones, London.
274. Parsons L. H., Smith A. D., Justice J. B. The in vivo microdialysis recovery of dopamine is altered independently of basal level by 6-hydroxydopamine lesions to the nucleus accumbens. J. Neurosci. Methods. 40:1991;139-147.
275. Pasinetti G. M., Osterburg H. H., Kelly A. B., Kohama S., Morgan D. G., Reinhard J. F., Stellwagen R. H., Finch C. E. Slow changes of tyrosine hydroxylase gene expression in dopaminergic brain neurons after neurotoxin lesioning: a model for neuron aging. Mol. Brain Res. 13:1992;63-73.
276. Pechan P. A., Chowdhury K., Gerdes W., Seifert W. Glutamate induces the growth factors NGF, bFGF, the receptor FGF-R1, and c-fos mRNA expression in rat astrocyte culture. Neurosci. Lett. 153:1993;111-114.
277. Penit-Soria J., Durand C., Hervé D., Besson M.-J. Morphological and biochemical adaptations to unilateral dopamine denervation of the neostriatum in newborn rats. Neuroscience. 77:1997;753-766.
278. Perez-Otaño I., Herrero M.-T., Oset C., DeCeballos M. L., Luquin M. R., Obeso J. A., Río J. D. Extensive loss of brain dopamine and serotonin induced by chronic administration of MPTP in the marmoset. Brain Res. 567:1991;127-132.
279. 2 type dopamine receptors in patients with Parkinson's disease and progressive supranuclear palsy. J. Neurol. Sci. 86:1988;291-306.
280. Plunkett R. J., Bankiewicz K. S., Cummings A. C., Miletich R. S., Schwartz J. P., Oldfield E. H. Evaluation of hemiparkinsonian monkeys after adrenal autografting or cavitation alone. J. Neurosurg. 73:1990;918-926.
281. Poewe, W. (1993). The preclinical phase of Parkinson's disease. In Advances in research on neurodegeneration (Ed. D. B. Calne), pp. 43-53. Birkhäuser, Boston.
282. Pollack P., Benabid A. L., Gross C., Gao D. M., Laurent A., Benazzouz A., Hoffmann D., Gentil M., Perret L. Effects of high frequency stimulation of subthalamic nucleus in Parkinson's disease. Rev. Neurol. 149:1993;175-176.
283. Porras A., Mora F. Dopamine-glutamate-GABA interactions and aging: studies in the striatum of the conscious rat. Eur. J. Neurosci. 7:1995;2183-2188.
284. Przedborski S., Levivier M., Kostic V., Jackson-Lewis V., Dollison A., Gash D. M., Fahn S., Cadet J. L. Sham transplantation protects 6-OHDA-induced dopaminergic toxicity in rats: behavioural and morphological evidence. Brain Res. 550:1991;231-238.
285. Pucak M. L., Grace A. A. Effects of haloperidol on the activity and membrane physiology of substantia nigra dopamine neurons recorded in vitro. Brain Res. 713:1996;44-52.
286. 2 receptors in adult rat neostriatum after neonatal dopamine denervation: quantitative data from ligand binding, in situ hybridization and iontophoresis. Neuroscience. 57:1993;635-648.
287. Raisman-Vozari R., Girault J.-A., Mussaoui S., Feuerstein C., Jenner P., Marsden C. D., Agid Y. Lack of change in striatal DARPP-32 following nigrostriatal dopaminergic lesions in animals and in parkinsonian syndromes in man. Brain Res. 507:1990;45-50.
288. Rajput A. H., Stern W., Laverty W. H. Chronic low-dose levodopa therapy in Parkinson's disease: an argument for delaying levodopa therapy. Neurology. 34:1984;991-996.
289. Reid M. S., HÜkfelt T., Herrera-Marschitz M., Hakanson R., Feng D. M., Folkers K., Goldstein M., Ungerstedt U. Intranigral substance P stimulation of striatal dopamine release is inhibited by Spantide II: a new tachykinin antagonist without apparent neurotoxicity. Brain Res. 532:1990;175-181.
290. Ribak C. E., Vaughn J. E., Roberts E. GABAergic nerve terminals decrease in the substantia nigra following hemitransections of the striatonigral and pallidonigral pathways. Brain Res. 192:1980;413-420.
291. Rice M. E., Cragg S. J., Greenfield S. A. Characteristics of electrically evoked somatodendritic dopamine release in substantia nigra and ventral tegmantal area in vitro. J. Neurophysiol. 77:1997;853-862.
292. Rinne U. K., Lönnberg P., Koskinen V. Dopamine receptors in parkinsonian brain. Brain Res. 359:1985;19-25.
293. Rinne U. K., Sonninen V., Laaksonen H. Responses of brain neurochemistry to levodopa treatment in Parkinson's disease. Adv. Neurol. 24:1979;259-274.
294. Robertson G. S., Damsma G., Fibiger H. C. Charaterization of dopamine release in the substantia nigra by in vivo microdialysis in freely moving rats. J. Neurosci. 11:1991;2209-2216.
295. Robinson T. E., Castaneda E., Whishaw I. Q. Compensatory changes in striatal dopamine neurons following recovery from injury induced by 6-OHDA or methamphetamine: a review of evidence from microdialysis studies. Can. J. Psycho. 44:1990;253-275.
296. Robinson T. E., Whishaw I. Q. Normalization of extracellular dopamine in striatum following recovery from a partial unilateral 6-OHDA lesion of the substantia nigra: a microdialysis study in freely moving rats. Brain Res. 450:1988;209-224.
297. Ross S. B. Synaptic concentration of dopamine in the mouse striatum in relationship to the kinetic properties of the dopamine receptors and uptake mechanism. J. Neurochem. 56:1991;22-29.
298. Rothblat D. S., Schneider J. S. Response of caudate neurons to stimulation of intrinsic and peripheral afferents in normal, symptomatic and recovered MPTP-treated cats. J. Neurosci. 13:1993;4372-4378.
299. Ruottinen H. M., Rinne U. K. Entacapone prolongs levodopa response in a one month double blind study in parkinsonian patients with levodopa-related fluctuations. J. Neurol. Neurosurg. Ps. 60:1996;36-40.
300. Sandstrom, M. and Bruno, J. P. (1997). Neurobehavioral functions of residual striatal DA in rats treated with 6-OHDA as weanlings vs as adults. Paper presented at the Soc. Neurosci. Abstr., New Orleans.
301. + on nigral and bilateral striatal release of dopamine simultaneously recorded by microdialysis. Brain Res. 538:1991;226-230.
302. Santiago M., Westerink B. H. C. The regulation of dopamine release from nigrostriatal neurons in conscious rats: the role of somatodendritic autoreceptors. Eur. J. Pharmacol. 204:1991;79-85.
303. Savasta, M., Cavorsin, M. L., Dentresangle, C. and Leviel, V. (1996). Measurement of DOPAC levels in the partially dopaminergic-denervated striatum in the rat brain. Paper presented at the Soc. Neurosci. Abstr., Washington.
304. Scarnati E., Proia A., Campana E., Pacitti C. Pedunculopontine-evoked excitation of substantia nigra neurons in the rat. Brain Res. 304:1984;351-361.
305. Scarnati E., Proia A., Campana E., Pacitti C. A microiontophoretic study on the nature of the putative synaptic neurotransmitter involved in the pedunculopontine-substantia nigra pars compacta excitatory pathway of the rat. Exp. Brain Res. 62:1986;470-478.
306. Scarnati E., Proia A., DiLoreto S., Pacitti C. The reciprocal electrophysiological influence between the nucleus tegmenti pedunculopontinus and the substantia nigra neurons in normal and decorticated rats. Brain Res. 423:1987;116-124.
307. Schepard P. D., German D. C. Electrophysiological and pharmacological evidence for the existence of distinct subpopulations of nigrostriatal dopaminergic neurons in the rat. Neuroscience. 27:1988;537-546.
308. Scherman D., Desnos C., Darchen F., Pollack P., Javoy-Agid F., Agid Y. Striatal dopamine deficiency in Parkinson's disease: role of aging. Ann. Neurol. 26:1989;551-557.
309. Schneider J. S. Chronic exposure to low doses of MPTP. II. Neurochemical and pathological consequences in cognitively-impaired, motor asymptomatic monkeys. Brain Res. 534:1990;25-36.
310. Schneider J. S., Kovelowski C. J. Chronic exposure to low doses of MPTP. I. Cognitive deficits in motor asymptomatic monkeys. Brain Res. 519:1990;122-128.
311. Schneider, J. S., McLaughlin, W. W. and Roeltgen, D. P. (1992a). Motor and non-motor behavioral deficits in monkeys made hemiparkinsonian by intracarotid MPTP infusion. Neurology 42, 1565-1572.
312. Schneider, J. S., Pope, A., Simpson, K., Taggart, J., Smith, M. G. and DiStefano, L. (1992b). Recovery from experimental Parkinsonism in primates with GM1 ganglioside treatment. Science 256, 843-846.
313. Schneider J. S., Rothblat D. S., DiStefano L. Volume transmission of dopamine over large distances may contribute to recovery from experimental parkinsonism. Brain Res. 643:1994;86-91.
314. Schoenfeld R., Uretsky N. Altered response to apomorphine in 6-hydroxydopamine-treated rats. Eur. J. Pharmacol. 19:1972;115-118.
315. Schultz W. Activity of dopamine neurons in the behaving primate. Seminars in the neurosciences. 4:1992;129-138.
316. Schultz W., Ungerstedt U. Short-term increase and long-term reversion of striatal cell activity after degeneration of the nigrostriatal dopamine system. Exp. Brain Res. 33:1978;159-171.
317. Schulzer M., Lee C. S., Mak E. K., Vingerhoets F. J. G., Calne D. B. A mathematical model of pathogenesis in idiopathic parkinsonism. Brain. 117:1994;509-516.
318. Schwartz J. P., Nishiyama N. Neurotrophic factor gene expression in astrocytes during development and following injury. Brain Res. Bull. 35:1994;403-407.
319. 2 receptor-like immunoreactivity in midbrain dopamine neurons and their striatal targets. J. Neurosci. 14:1994;88-106.
320. Shangera M. K., Trulson M. E., German D. C. Electrophysiological properties of mouse dopamine neurons: in vivo and in vitro studies. Neuroscience. 12:1984;783-801.
321. 2 interaction in feedback control of midbrain dopamine neurons. J. Neurosci. 17:1997;7988-7994.
322. Shim S. S., Bunney B. S., Shi W.-X. Effects of lesions in the medial prefrontal cortex on the activity of midbrain dopamine neurons. Neuropsychopharmacol. 15:1996;437-441.
323. Silbergeld E. K., Walters J. R. Synaptosomal uptake and release of dopamine in substantia nigra: effect of GABA and substance P. Neurosci. Lett. 12:1979;119-126.
324. Smith I. D., Grace A. A. Role of the subthalamic nucleus in the regulation of nigral dopamine neuron activity. Synapse. 12:1992;287-303.
325. Smith R. D., Zhang Z., Kurlan R., McDermott M., Gash D. M. Developing a stable bilateral model of parkinsonism in rhesus monkeys. Neuroscience. 52:1993;7-16.
326. Smith Y., Hazrati L. N., Parent A. Efferent projections of the subthalamic nucleus in the squirrel monkey as studied by the PHA-L anterograde tracing method. J. Comp. Neurol. 259:1990;306-323.
327. Smith Y., Paquet M., Charara A., Parent A., Soghomonian J. J. Glutamate inputs to midbrain dopaminergic neurones in primates: synaptic relationships and localization of glutamate receptor subunits. Mov. Disord. 12(suppl. 1):1997;139.
328. Snyder G. L., Keller R. W., Zigmond M. J. Dopamine efflux from striatal slices after intracerebral 6-hydroxydopamine: evidence for compensatory hyperactivity of residual terminals. J. Pharmacol. Exp. Ther. 253:1990;867-876.
329. Snyder, G. L., Stachowiak, M. K., Keller, R. W., Stricker, E. M. and Zigmond, M. J. (1986). Release of endogenous DA and DOPAC from striatal slices after DA-depleting lesions: effects of stimulation frequency and DA synthesis inhibition. Paper presented at the Soc. Neurosci. Abstr., Washington.
330. Stachowiak M. K., Keller R. W., Stricker E. M., Zigmond M. J. Increased dopamine efflux from striatal slices during development and after nigrostriatal bundle damage. J. Neurosci. 7:1987;1648-1654.
331. Starke K., Reinmann W., Zumstein A., Herrting G. Effect of dopamine receptor agonists on release of dopamine in the rabbit caudate nucleus in vitro. Naunyn-Schmiedeberg's Arch. Pharmacol. 305:1978;27-36.
332. 3H dopamine release from slices of rat substantia nigra and corpus striatum. Eur. J. Pharmacol. 48:1978;325-328.
333. Starr M. S. Investigation of possible interactions between substance P and transmitter mechanisms in the substantia nigra and corpus striatum of the rat. J. Pharm. Pharmac. 30:1978;359-363.
334. 2 balance in the basal ganglia and its relevance to Parkinson's disease. Synapse. 19:1995;264-293.
335. Stoessl A. J., Rajakumar N. Effects of subthalamic nucleus lesions in a putative model of tardive dyskinesia in the rat. Synapse. 24:1996;256-261.
336. Strada O., Hirsch E. C., Javoy-Agid F., Duyckaerts C., Hauw J. J., Agid Y. Low affinity nerve growth factor receptor, adrenal transplant and Parkinson's disease. J. Neurol. Sci. 120:1993;33-37.
337. Stricker, E. M. and Zigmond, M. J. (1986). Brain monoamines, homeostasis, and adaptative behavior. In Handbook of Physiology, intrinsic regulatory systems of the brain (Ed. F. Bloom), vol. IV, pp. 677-696. Am. Physiol. Soc., Bethesda.
338. Svennilson E., Torvik A., Lowe R., Leksell L. Treatment of parkinsonism by stereotaxic thermolesions in the pallidal region. Acta Psychiat. Neurol. Scand. 35:1960;358-377.
339. Takeuchi H., Young S. T., Groves P. M. Dopaminergic terminal excitability following arrival of the nerve impulse: the influence of amphetamine and haloperidol. Brain Res. 245:1982;47-56.
340. Tashiro, Y., Kaneko, T., Sugimoto, T., Nagatsu, I., Kikuchi, H. and Mizuno, N. (1989a) Striatal neurons with aromatic L-amino acid decarboxylase-like immunoreactivity in the rat. Neurosci. Lett. 100, 29-34.
341. Tashiro, Y., Sugimoto, T., Hattori, T., Uemura, Y., Nagatsu, I., Kikuchi H. and Mizuno, N. (1989b) Tyrosine hydroxylase-like immunoreactive neurons in the striatum of the rat. Neurosci. Lett. 97, 6-10.
342. Tepper J. M., Martin L. P., Anderson D. R. GABAA receptor-mediated inhibition of rat substantia nigra dopaminergic neurons by pars reticulata projection neurons. J. Neurosci. 15:1995;3092-3103.
343. Thornburg J. E., Moore K. E. Supersensitivity to dopa-mine agonists following unilateral, 6-hydroxydopamine-induced striatal lesions in mice. J. Pharmacol. Exp. Ther. 192:1975;42-49.
344. Toffano G., Savoini G., Moroni F., Lombardi G., Calza L., Agnati L. F. GM1 ganglioside stimulates the regeneration of dopaminergic neurons in the central nervous system. Brain Res. 261:1983;163-166.
345. Tokuno H., Moriizumi T., Kudo M., Nakamura Y. A morphological evidence for monosynaptic projections from the nucleus tegmenti pedunculopontinus pars compacta (TPC) to nigrostriatal projection neurons. Neurosci. Lett. 85:1988;1-4.
346. Tomac A., Lindqvist E., Lin L. F. H., Ügren S. O., Young D., Hoffer B. J., Olson L. Protection and repair of the nigrostriatal dopaminergic system by GDNF in vivo. Nature. 373:1995;335-341.
347. Tong Z. Y., Overton P. G., Clark D. Stimulation of the prefrontal cortex in the rat induces patterns of activity in midbrain dopaminergic neurons which resemble natural burst events. Synapse. 22:1996;195-208.
348. Ungerstedt, U., Ljungberg, T., Hoffer, B. and Siggins, G. (1975). Dopaminergic supersensitivity in the striatum. In Advances in neurology (Eds D. B. Calne, T. N. Chase, and A. Barbeau), Vol. 9, pp. 57-65. Raven Press, New York.
349. Uretsky N. J., Simmonds M. A., Iversen L. L. Changes in the retention and metabolism of 3H-L-norepinephrine in rat brain in vivo after 6-hydroxydopamine pretreatment. J. Pharmacol. Exp. Ther. 176:1971;489-496.
350. Varastet M., Riche D., Maziere M., Hantraye P. Chronic MPTP treatment reproduces in baboons the differential vulnerability of mesencephalic dopaminergic neurons observed in Parkinson's disease. Neuroscience. 63:1994;47-56.
351. Walaas S. I., Aswaad S. W., Greengard P. A dopamine-and cyclic AMP-regulated phosphoprotein enriched in dopamine-innervated brain regions. Nature. 301:1984;69-71.
352. Wichmann T., DeLong M. R. Functional and pathophysiological models of the basal ganglia. Curr. Opin. Neurobiol. 6:1996;751-758.
353. Williams, G. V. and Millar, J. (1990a). Concentration-dependent actions of stimulated dopamine release on neuronal activity in the rat striatum. Neuroscience 39, 1-16.
354. Williams, G. V. and Millar, J. (1990b). Differential actions of endogenous and iontophoretic dopamine in rat striatum. Eur. J. Neurosci. 2, 658-661.
355. Wilson C. J., Fenster G. A., Young S. J., Groves P. M. Haloperidol-induced alteration of post-firing inhibition in dopaminergic neurons of rat substantia nigra. Brain Res. 179:1979;165-170.
356. Wilson C. J., Young S. J., Groves P. M. Statistical properties of neuronal spike trains in the substantia nigra: cell types and their interactions. Brain Res. 136:1977;243-360.
357. Yahr M. D., Duvoisin R. C., Hoehn M. M., Schear M. J., Barrett R. E. L-Dopa: its clinical effects in parkinsonism. Trans. Amer. Neurol. Ass. 93:1968;56-63.
358. Yoshida M., Precht W. Monosynaptic inhibition of neurons of the substantia nigra by caudato-nigral fibers. Brain Res. 32:1971;225-228.
359. 2 dopamine receptors in the basal ganglia of the rat: light and electron microscopy. Neuroscience. 65:1995;709-730.
360. Zetterstrom T., Sharp T., Marsen C. A., Ungerstedt U. in vivo measurement of dopamine and its metabolites by intracerebral dialysis: changes after d-amphetamine. J. Neurochem. 41:1983;1769-1773.
361. Zhang J., Chiodo L. A., Freeman A. S. Influence of excitatory amino acid receptor subtypes on the electrophysiological activity of dopaminergic neurons in rat substantia nigra. J. Pharmacol. Exp. Ther. 269:1994;313-321.
362. Zhang W. Q., Tilson H. A., Nanry K. P., Hudson P. M., Hong J.-S., Stachowiak M. K. Increased dopamine release from striata of rats after unilateral nigrostriatal bundle damage. Brain Res. 461:1988;335-342.
363. Zhou F. C., Bledsoe S., Murphy J. Serotoninergic sprouting is induced by dopamine-lesion in substantia nigra of adult rat brain. Brain Res. 556:1991;108-116.
364. Zigmond M. J. Do compensatory processes underlie the preclinical phase of neurodegenerative disease? Insights from an animal model of parkinsonism. Neurobiol. Dis. 4:1997;247-253.
365. Zigmond M. J., Abercrombie E. D., Berger T. W., Grace A. A., Stricker E. M. Compensations after lesions of central dopaminergic neurons: some clinical and basic implications. Trends Neurosci. 13:1990;290-296.
366. Zigmond, M. J., Abercrombie, E. D., Berger, T. W., Grace, A. A. and Stricker, E. M. (1993). Compensatory responses to partial loss of dopaminergic neurons: studies with 6-hydroxydopamine. In Current concepts in Parkinson's disease research (Eds J. S. Schneider, and M. Gupta), pp. 99-140. Hogrefe and Huber, Toronto.
367. Zigmond M. J., Acheson A. L., Stachowiak M. K., Stricker E. M. Neurochemical compensation after nigrostriatal bundle injury in an animal model of preclinical parkinsonism. Arch. Neurol. 41:1984;856-861.
368. Zigmond M. J., Stricker E. M. Recovery of feeding and drinking by rats after intraventricular 6-hydroxydopamine or lateral hypothalamic lesions. Science. 182:1973;717-719.
369. Zigmond M. J., Stricker E. M. Supersensitivity after intraventicular 6-hydroxydopamine: relation to dopamine depletion. Experientia. 36:1980;436-438.
370. Zigmond, M. J. and Stricker, E. M. (1985). Adaptative properties of monoaminergic neurons. In Handbook of Neurochemistry (Ed. A. Lajtha), Vol. 9, pp. 87-102. Plenum Press, New York.
371. Zigmond M. J., Stricker E. M. Animal models of parkinsonism using selective neurotoxins: clinical and basic implications. Int. Rev. Neurobiol. 31:1989;1-79.
372. Zigmond R. E., Schwarzschild M. A., Rittenhouse A. R. Acute regulation of tyrosine hydroxylase by nerve activity and by neurotransmitters via phosphorylation. Ann. Rev. Neurosci. 12:1989;415-461.
373. Zoli M., Fuxe L. F. Wiring and volume transmission in the central nervous system: the concept of closed and open synapses. Prog. Neurobiol. 49:1996;363-380.